Probiotic Survey in Cancer Patients Treated in the Outpatient Department in a Comprehensive Cancer Center

Sona Ciernikova, Michal Mego, Maria Semanova, Lenka Wachsmannova, Zuzana Adamcikova, Viola Stevurkova, Lubos Drgona, Vladimir Zajac, Sona Ciernikova, Michal Mego, Maria Semanova, Lenka Wachsmannova, Zuzana Adamcikova, Viola Stevurkova, Lubos Drgona, Vladimir Zajac

Abstract

Purpose: Availability without prescription restriction, low cost, and simple oral administration allow cancer patients to use probiotics without knowledge of potential risks. We present a survey of probiotic use and the association with patient tumor characteristics in cancer patients treated at the outpatient department of the National Cancer Institute in Slovakia.

Patients and methods: Between March and December 2014, 499 patients were asked to evaluate their overall experience with probiotics by questionnaire form, including the length and method of use relative to anticancer therapy, expectations, side-effect experiences, understanding of the possible risks, dietary supplement use, and others. The relevant data were statistically evaluated.

Results: The cohort consisted of 323 women (64.7%) and 176 men (35.3%); 91.6% were undergoing chemotherapy (2.6% together with radiotherapy) and 8.4% had no anticancer therapy. The prevalence of probiotic use was 28.5% and only 12 patients using probiotics (8.5%) described negative side effects. Most patients declared consideration of probiotic use based on recommendation from a physician (37.3%) or a pharmacist (14.8%). Nevertheless, up to 86.6% of patients declared no knowledge of possible risks. Statistically significant correlation was found between probiotic use and age of patients (P < .008), gender (P < .023), and taking other dietary supplements (P < .000002).

Conclusions: In this prospective study, we present for the first time the prevalence, side-effect experience, and aspects that most likely influence probiotic use in cancer patients. Minimal knowledge of risks underlines the importance of an active approach by oncologists to inform patients about probiotic safety.

Keywords: cancer; chemotherapy; dietary supplements; immunocompromised cancer patients; oncologist to patient communication; probiotics; safety.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505-14.
    1. Norman HA, Butrum RR, Feldman E, et al. The role of dietary supplements during cancer therapy. J Nutr. 2003;133:3794S-3799S.
    1. Wanchai A, Armer JM, Stewart BR. Complementary and alternative medicine use among women with breast cancer: a systematic review. Clin J Oncol Nurs. 2010;14:E45-E55.
    1. Astin JA, Reilly C, Perkins C, Child WL. Breast cancer patients’ perspectives on and use of complementary and alternative medicine: a study by the Susan G. Komen Breast Cancer Foundation. J Soc Integr Oncol. 2006;4:157-169.
    1. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365-378.
    1. Food and Agricultural Organization of United Nations and World Health Organization. Evaluation of Health and Nutritional Properties of Probiotics in Food, Including Powder Milk With Live Lactic Acid Bacteria. Geneva, Switzerland: FAO, WHO. Expert Consultation report; 2001.
    1. Goto Y, Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev. 2012;245:147-163.
    1. Ciernikova S, Mego M, Hainova K, Adamcikova Z, Stevurkova V, Zajac V. Modification of microflora imbalance: future directions for prevention and treatment of colorectal cancer? Neoplasma. 2015;62:345-352.
    1. Kurokawa K, Itoh T, Kuwahara T, et al. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res. 2007;14:169-181.
    1. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
    1. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959-1969.
    1. Sharma V, Garg S, Aggarwal S. Probiotics and liver disease. Perm J. 2013;17:62-67.
    1. He T, Priebe MG, Zhong Y, et al. Effects of yogurt and bifidobacteria supplementation on the colonic microbiota in lactose-intolerant subjects. J Appl Microbiol. 2007;104:595-604.
    1. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
    1. Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48-57.
    1. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.
    1. Gibson RJ, Keefe DM, Lalla RV, et al. ; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2013;21:313-326.
    1. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol. 2001;13:391-396.
    1. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13:912-915.
    1. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048.
    1. Barton LL, Rider ED, Coen RW. Bacteremic infection with Pediococcus: vancomycin resistant opportunist. Pediatrics. 2001;107:775-776.
    1. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005;24:278-280.
    1. Ledoux D, Labombardi VJ, Karter D. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin’s disease. Int J STD AIDS. 2006;17:280-282.
    1. Richard V, Van der Auwera P, Snoeck R, Daneau D, Meunier F. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis. 1988;7:783-785.
    1. Tommasi C, Equitani F, Masala M, et al. Diagnostic difficulties of Lactobacillus casei bacteraemia in immunocompetent patients: a case report. J Med Case Rep. 2008;2:315.
    1. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47:437-439.
    1. Burkhardt O, Köhnlein T, Pletz M, Welte T. Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis. 2005;37:69-72.
    1. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38:457-458.
    1. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115:178-181.
    1. Lestin F, Pertschy A, Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr. 2003;128:2531-2533.
    1. Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol. 1998;36:325-326.
    1. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156:679-681.
    1. Zein EF, Karaa S, Chemaly A, Saidi I, Daou-Chahine W, Rohban R. Lactobacillus rhamnosus septicemia in a diabetic patient associated with probiotic use: a case report. Ann Biol Clin (Paris). 2008;66:195-198.
    1. Muñoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634.
    1. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008;26:665-673.
    1. Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views, knowledge and interactions with doctors: a qualitative study. BMC Complement Altern Med. 2006;6:40.
    1. Lakritz JR, Poutahidis T, Levkovich T, et al. Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice. Int J Cancer. 2014;135:529-540.
    1. Aragón F, Carino S, Perdigón G, de Moreno de, LeBlanc A. The administration of milk fermented by the probiotic Lactobacillus casei CRL 431 exerts an immunomodulatory effect against a breast tumour in a mouse model. Immunobiology. 2014;219:457-464.
    1. Mohania D, Kansal VK, Kruzliak P, Kumari A. Probiotic dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum modulates the formation of aberrant crypt foci, mucin-depleted foci, and cell proliferation on 1,2-dimethylhydrazine-induced colorectal carcinogenesis in Wistar rats. Rejuvenation Res. 2014;17:325-333.
    1. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer. 2000;8:504-505.
    1. Fruchart C, Salah A, Gray C, et al. Lactobacillus species as emerging pathogens in neutropenic patients. Eur J Clin Microbiol Infect Dis. 1997;16:681-684.
    1. Mego M, Ebringer L, Drgona L, et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74: pilot study phase I. Neoplasma. 2005;52:159-164.
    1. Schultz M, Baranchi A, Thurston L, et al. Consumer demographics and expectations of probiotic therapy in New Zealand: results of a large telephone survey. N Z Med J. 2011;124:36-43.
    1. Mego M, Koncekova R, Mikuskova E, et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74: phase II study. Support Care Cancer. 2006;14:285-290.
    1. Fuccio L, Guido A, Eusebi LH, et al. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. J Clin Gastroenterol. 2009;43:506-513.
    1. Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23:356-362.
    1. Cassileth BR, Heitzer M, Wesa K. The public health impact of herbs and nutritional supplements. Pharm Biol. 2009;47:761-767.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere